OBJECTIVE: Proximal chromosome 10q26 was recently linked to waist/hip ratio in European and African-American families. The objective was to investigate whether genomic variation in chromosome 10q26.11 reflects variation in obesity-related clinical parameters in a Swedish population. DESIGN: Genetic association study of single-nucleotide polymorphisms (SNPs) in chromosome 10q26.11 and obesity-related clinical parameters was performed. Obesity was defined as body mass index (BMI)Z30 kg/m 2 . SUBJECTS: Swedish Caucasians comprising 276 obese and 480 nonobese men, 313 obese and 494 nonobese women, 177 obese and 163 nonobese patients with type 2 diabetes mellitus (T2DM), and 106 obese and 201 nonobese subjects with impaired glucose tolerance (IGT) patients. MEASUREMENTS: Genotypes of 11 SNPs at chromosome 10q26.11, and various obesity-related clinical parameters. RESULTS: Homozygosity of a common haplotype constructed by three SNPs, rs2185937, rs1797 and hCV1402327, covering an interval of 2.7 kb, was suggested to confer an increased risk for obesity of 1.5 among men (P ¼ 0.043). The C allele frequency and homozygous genotype frequency of the rs1797 tended to be higher among obese compared to among nonobese men (P ¼ 0.017 and 0.020, respectively). The distribution of BMI and diastolic blood pressure was higher among those with the C/C genotype (P ¼ 0.022 and 0.0061, respectively). The obese and the nonobese groups were homogeneous over BMI subgroups with regard to rs1797 risk genotype distribution. There was no tendency for association between rs1797 and obesity among neither women nor T2DM nor IGT patients. CONCLUSION: We show support for association between proximal chromosome 10q26.11 and obesity among Swedish men but not women through the analysis of a haplotype encompassing 2.7 kb.
Introduction
Obesity is a profound health and socioeconomic burden. The World Health Organization has declared obesity to be the greatest health threat facing the West. 1 Genetic factors play a principal role in determining body weight within a given environment. Family, twin and adoption studies have reported estimates of heritability for body mass index (BMI) to be between 50 and 90%. 2 In total, 90 genes have been associated with obesity or related phenotypes, out of which 15 genes have been supported by at least five studies. 3 Human chromosome 10q25-q26 is syntenic to several quantitative trait loci (QTLs) for body weight and type 2 diabetes mellitus (T2DM) in rats. [4] [5] [6] Dong et al 7 recently
reported linkage between a QTL on proximal chromosome 10q26 and waist/hip ratio (WHR) in a sample of 200 European American families having 542 siblings and 44 African-American families having 125 siblings. Linkage was found to the microsatellites D10S1679, D10S587 and D10S1656 covering an interval of 6.7 cM (family-specific nonparametric linkage score Z ¼ 2.2). We hypothesized that genomic variation in this 10q26 region would reflect variation in obesity-related clinical parameters in a Swedish population. To test that, and to more closely delineate the location of the underlying functional polymorphism, we performed an association study on a sample of obese and nonobese Swedish men and women.
Material and methods

Subjects
The study group consisted of unrelated men and women who were either (i) healthy control subjects with varying BMI; or (ii) referred to Huddinge University Hospital, Stockholm County for uncomplicated hernia, gallstones or uncomplicated obesity; or (iii) patients with T2DM or subjects with impaired glucose tolerance (IGT) from the Stockholm Diabetes Prevention Program (SDPP). All individuals were Caucasian, Swedish nationals and lived in the communities within the Stockholm County. Obesity was defined as BMIZ30 kg/m 2 , according to the WHO criteria, whereas nonobese individuals were those with BMIo30 kg/m 2 . The group of obese, otherwise healthy, individuals included 276 men and 313 women, and the nonobese, healthy group comprised 480 men and 494 women. None of these obese or nonobese individuals had other known metabolic disorder, including diabetes, familial combined hyperlipidemia, polycystic ovary disease or thyroid disturbance. Also, none of the individuals was completely sedentary, involved in athletic performance or had undertaken any weight-reduction effort during the last 6-months. The T2DM obese group included 112 men and 65 women, whereas the T2DM nonobese group comprised 101 men and 62 women. The IGT obese group consisted of 53 men and 53 women and the IGT nonobese group included 110 men and 91 women. None of the subjects with T2DM and IGT were under medical treatment. Information on hypertension medication was not available. Age and BMI distribution parameters are given in Table 1 . Gender-specific age difference between the obese and the corresponding nonobese group was found only for healthy females with the obese group having lower age distribution (P ¼ 0.02, Kruskal-Wallis test). After an overnight fast, the participants were examined for the clinical metabolic parameters: BMI, body fat mass (BFM, determined by bioimpedance (Model TBF305, Tanita Corporation, Tokyo, Japan)), WHR (supine position), systolic and diastolic blood pressure (SBP, DBP, supine position) and plasma levels of glucose, insulin, triglycerides, cholesterol and HDL-cholesterol. Plasma variables were measured by the hospitals accredited routine chemistry laboratory. The distributions of the parameters for the obese and the nonobese men without other metabolic disorder are given in Table 2 . The 0 . Each 96-well PCR plate contained at least one negative control (no template). In each plate, eight PCR products including a negative control were size-controlled by gel electrophoresis.
The PCR products were prepared for Pyrosequencingt (PSQt) using streptavidin-coated sepharose beads and the Vacuum Prep Tool (Pyrosequencing AB, Uppsala, Sweden), and the PSQt reactions were performed on a PSQ96t instrument using the PSQ96t SNP reagent kit (Pyrosequencing AB), both steps according to the manufacturer's instructions. The sequencing primers were for rs2185937 5 0 -TGGTCACTCTACTGATC-3; for rs1797 5 0 -GAAGACGGCAT TTGT-3 0 ; for hCV1402327 5 0 -AAGTGGAGGGAATTATGC-3 0 . The PSQ96t plates contained the same sample sets as the PCR plates, including the negative controls.
Statistical analysis
Hardy-Weinberg equilibrium test was applied on the nonobese healthy individuals to ensure independent segregation of alleles. 8 Linkage disequilibrium between markers was estimated among the nonobese men using Lewontins D 0 .
9
Difference in allele distribution between gender-specific obese and nonobese groups was tested using two-sided Fisher's exact test. Genotype distribution between genderspecific obese and nonobese groups was tested (i) using the Pearson w 2 test (2 df) and (ii) assuming a recessive model using two-sided Fisher's exact test and logistic regression with age as covariate. These analyses were performed using STATA version 6.0 (Stata Corporation, College Station, TX, USA). Other quantitative clinical parameters including WHR, SBP, DBP, BFM and plasma levels of glucose, insulin, triglycerides, cholesterol and HDL cholesterol, were also assessed for dependence on rs1797 genotype among non-T2DM and non-IGT men, using STATA. For this, parameter distributions were normalized when necessary by natural logarithm-transformation. Variance equality between genotype groups was assessed using Bartlett's test. Testing for differences among clinical parameters between genotype groups was then performed using univariate two-way ANOVA, with age as predictor, or two-sided t-test for parameters with unequal variances. Non-normally distributed parameters were tested with nonparametric KruskalWallis test. Similar analyses were carried out when testing significance of clinical parameter difference between the nonobese and the obese group. Haplotype frequency estimates were calculated using Arlequin ver 2.0.1.1.
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Heterogeneity in haplotype frequency distribution between the obese and nonobese men was tested by calculating the test statistic 2 Â (log-likelihood Nonobese þ log-likelihood Obese Àlog-likelihood Combined ), which has a w 2 distribution with nÀ1 degrees of freedom (n is the number of haplotypes). 9 
Bioinformatics
To detect putative genes in the vicinity of rs1797, the sequence between 2.9 kb upstream rs2420467 and 1.0 kb downstream hCV11201918, (obtained from contig ID: AL390244.19.1.101530, www.ensembl.org) was translated Chromosome 10q26.11 and obesity C Lavebratt et al into all six reading frames using sixpack from the EMBOSS suite. 11 Detected open reading frames (ORFs) encoding peptides longer than 100 amino-acid residues were analyzed for homology with proteins in the UniProt database.
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Results
Genetic variation in proximal chromosome 10q26.11 was studied for association to obesity in a Swedish case control sample of 276 obese and 480 nonobese men without other metabolic disorder. In total, 11 SNPs located in a region spanning 4.3 Mb (Table 3 ) of chromosome 10q26.11 were genotyped, suggesting a multiple testing correction giving threshold for significance at P ¼ 0.005 (0.05/10 (number of SNPs minus one)). However, this correction is highly conservative especially since three of the SNPs are in tight LD (P ¼ 6 Â 10 À140 between rs2185937 and hCV1402327).
Po0.05 was regarded as suggestive significance. Allele frequencies of all SNPs were in Hardy-Weinberg equilibrium. All SNPs were common, with minor allele frequency Z0.14 ( Table 3 ). The obese men tended to have a higher frequency of the minor allele rs1797: C compared to the nonobese men (P ¼ 0.017, Table 4 ). Likewise, the C/C genotype for rs1797 tended to be more common among the obese compared to among the nonobese men (OR ¼ 1.53, P ¼ 0.020, Table 5 ). In Table 6 ). The rs1797 genotype distribution in subgroups of the obese and the nonobese groups was studied. The ratio, C/C/(T/T þ T/C), was similar for the subgroups within each of the obese and the nonobese group (obese group: 4 df, P ¼ 0.69; nonobese group: 2 df P ¼ 0.79; Table 7 ). DBP and BMI correlated fairly well (r ¼ 0.45, n ¼ 657, 95% CI: 0.38-0.51) and DBP was higher among the obese compared to among the nonobese men (Po0.00005, Table 2 ). Accordingly, the DBP was higher among those with rs1797 C/C genotype (F ¼ 7.56, 1 df, P ¼ 0.0061 from ANOVA with age as covariate; w 2 ¼ 7.7, 1 df, P ¼ 0.0054 from Kruskal-Wallis test, Table 6 ). The association between rs1797 and obesity was supported by subsample genotype data from the surrounding SNPs rs2185937, hCV1402327 and hCV11201918 located 0.7 kb upstream, 2 and 7 kb downstream rs1797, respectively (Table 3 , right column). In the whole sample, homozygosity for the hCV1402327 minor allele G tended to be more common among obese compared to among nonobese men (OR ¼ 1.43, P ¼ 0.054), which is in agreement with the high interSNP LD
) in relation to rs1797, had a corresponding OR of 1.32 (P ¼ 0.12) for minor allele C homozygosity. Homozygosity for the common rs2185937: C-rs1797: C-hCV1402327: G haplotype suggestively conferred an increased risk for obesity of 1.50 (P ¼ 0.043, Table 8 ). Haplotype frequencies were estimated among the obese and the nonobese men. The estimated frequency of the risk haplotype was 40% among the nonobese. There was a suggestive difference in estimated haplotype distribution between the obese and the nonobese men (OR ¼ 1.28, P ¼ 0.029 comparing the rs2185937: C-rs1797: C-rs1402327: G haplotype with the other haplotypes in group, Table 8 ). There was no association between rs1797 and the clinical parameters other than BMI and DBP among the men (P40.05, Table 6 ).
Women with no other metabolic disorder, as well as men and women with IGT or T2DM were studied for association between obesity and rs1797. No such association was found (Table 5) . Combining the data from the men with IGT or T2DM with those from men with no comorbidity masked the rs1797-obesity association detected among the men with no comorbidity. The statistical power for suggestive detection (a ¼ 0.05) of OR (rs1797 C/C among obese subjects vs nonobese) Z1.5 was 0.59 and 0.68 for men and women without comorbidity, 0.36 and 0.30 for men and women with any of IGT or T2DM, and 0.78 and 0.80 for all men and all women, respectively.
There was no association for T2DM or IGT diagnose with rs1797 using healthy nonobese as controls (P40.55). The power to suggestively detect ORZ1.5 was 0.66 and 0.63 for males and females, respectively.
The sequence between 11 kb upstream and 8 kb downstream rs1797 did not contain any known gene. Bioinformatic analyses revealed two ORFs, encoding hypothetical peptides of more than 100 amino acids, located 1660 bp proximal rs2185937 and 4169 bp distal hCV1402327. These ORFs had 59-68% ungapped identity over 59-73 aa each to two hypothetical proteins expressed in human or macaque brain (Q9H3B5, Q9BGV8 and Q8N773, Q9N083 for the former and latter ORF, respectively). Nonparametric Kruskal-Wallis test. Table 7 Genotype distribution (n) within BMI-defined sub-groups of the obese and the nonobese men without metabolic comorbidity , in a population comprising 756 Swedish men without metabolic comorbidity. Homozygosity of a common haplotype constructed by three SNPs, rs2185937, rs1797 and hCV1402327, covering an interval of 2.7 kb was suggested to confer an increased risk for obesity of 1.5 (P ¼ 0.043). Allele frequency and homozygous genotype frequency of the rs1797 minor allele C tended to be higher among obese compared to among nonobese (BMI o30 kg/m 2 ) men (P ¼ 0.017 and 0.020, respectively), and the distribution of BMI and DBP was higher among those with the C/C genotype (P ¼ 0.022 and 0.0061, respectively). The obese and the nonobese groups were homogeneous over BMI subgroups with regard to rs1797 risk genotype distribution. There was no tendency for association between rs1797 and obesity neither among men with T2DM nor IGT, nor among women without or with any of these metabolic comorbidities.
In support of these data, linkage between proximal 10q26 and an obesity-related characteristic was recently demonstrated by Dong et hCV11290602 and rs1369 are located in CASC2 intron 1 and 3 0 -UTR, respectively. rs1369, with genotypes distributed independently from those of rs1797, showed a border-line tendency to have higher proportion of heterozygotes among obese men in a subsample (OR ¼ 1.56, 95% CI: 1.00-2.39, 1 df, P ¼ 0.057).
The trend for association between rs1797 and obesity was found exclusively among men. Gender-specific effects of genetic variation on measures of body mass and composition have been repeatedly demonstrated in several different gene studies. 3 Although obesity does not necessarily lead to T2DM, epidemiological studies have shown that the risk for T2DM increases exponentially with BMI over 28 kg/m 2 .
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In order to get an indication of whether variation in rs1797 influences obesity also in IGT and T2DM, we applied the genotyping to subjects with IGT and patients with T2DM. No such indication was found. Likewise, rs1797 did not seem to influence the development of T2DM. However, the sample sizes for obesity-subdivided T2DM and IGT groups were small, limiting the power to detect association. Including IGT and T2DM men impaired the rs1797-obesity association detected among non-IGT non-T2DM men. That may partially be explained by effect dilution from other genetic factors predisposing both obesity and insulin resistance among subjects with IGT and T2DM patients. 19 Moreover, an IGT or T2DM diagnose and thereby prescription of diet and regular exercise likely reduces BMI in these individuals. In summary, we show support for association between proximal chromosome 10q26.11 and obesity among Swedish 
